Duo Oncology Founders Publish in Advanced Science.

Founder-Inventors, Drs. Song Li and Jingjing Sun, Publish on Novel Ultrasmall Precision Nanomedicine.

PITTSBURGH (PRWEB) June 27, 2024 – Research led by Drs. Song Li and Jingjing Sun, the inventors behind Duo Oncology’s ultrasmall nanomedicine chemistry, was recently published in the prestigious journal, Advanced Science. The work titled, “In Situ Formation of Fibronectin-Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy”, reports on a beneficial targeting and uptake mechanism for DUO-209, a novel azacytidine prodrug nanomedicine.  These results set DUO-209 apart from prior cancer nanomedicines.

Drs. Li and Sun established proof-of-concept for serum protein-enhanced nanomedicine uptake in molecular binding studies, in cell-based assays, and finally, in tumor bearing mice.  “Our research on the azacytidine nanomedicine is the culmination of a multi-year effort,” said principal investigator, Dr. Song Li.  “The studies provide a key insight into how our prodrug nanomedicines can reach and penetrate tumors.”   Critical findings in two different models of lung cancer confirm also that the DUO-209 nanomedicine has an immune mediated mechanism of action and overcomes a known drug resistance.

“We are so pleased to see Drs. Li and Sun report these significant results in Advanced Science,” said Dr. Sam Rothstein. “Their work on the azacitidine prodrug nanomedicines helps advance Duo’s pipeline and bring innovative therapies to new orphan patient populations, including those with myelodysplastic syndromes or with juvenile leukemia. We look forward to bringing DUO-209 and other potent, ultrasmall nanomedicines to patients.”